Genitourinary malignancies (Q81086297)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16110626%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

review article

1 reference

title

Genitourinary malignancies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16110626%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

Shandra S Wilson

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16110626%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

E David Crawford

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16110626%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

publication date

1 January 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16110626%20AND%20SRC:MED&resulttype=core&format=json

Cancer chemotherapy and biological response modifiers

5 January 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16110626%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16110626%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

page(s)

485-513

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16110626%20AND%20SRC:MED&resulttype=core&format=json

The influence of finasteride on the development of prostate cancer

5 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Changes in molecular forms of prostate-specific antigen during treatment with finasteride

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Selenium supplementation, baseline plasma selenium status and incidence of prostate cancer: an analysis of the complete treatment period of the Nutritional Prevention of Cancer Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Vitamin D and vitamin D analogs as cancer chemopreventive agents

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Body mass index and risk of prostate cancer in U.S. health professionals

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Reduced circulating androgen bioactivity in patients with prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Androgens and the ageing male

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Interrelationships between plasma testosterone, SHBG, IGF-I, insulin and leptin in prostate cancer cases and controls

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Effects of lycopene supplementation in patients with localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Lectin and serum-PSA interaction as a screening test for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Diagnostic potential of serum proteomic patterns in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Serum proteomic patterns for detection of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Screening for prostate cancer: recommendation and rationale

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Randomized prospective trial of a novel local anesthetic technique for extensive prostate biopsy

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Periprostatic administration of local anesthesia during transrectal ultrasound-guided biopsy of the prostate: a randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Local anaesthetic for transrectal ultrasound-guided prostate biopsy: a prospective, randomized, double blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Noninvasive detection of clinically occult lymph-node metastases in prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Using the percentage of biopsy cores positive for cancer, pretreatment PSA, and highest biopsy Gleason sum to predict pathologic stage after radical prostatectomy: the Center for Prostate Disease Research nomograms

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Quality of life after radical prostatectomy or watchful waiting.

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Neoadjuvant flutamide monotherapy for locally confined prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Phase II study of paclitaxel plus gemcitabine in refractory germ cell tumors (E9897): a trial of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Incomplete glandular ablation after salvage cryotherapy for recurrent prostate cancer after radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Phase III Trial Comparing Whole-Pelvic Versus Prostate-Only Radiotherapy and Neoadjuvant Versus Adjuvant Combined Androgen Suppression: Radiation Therapy Oncology Group 9413

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy: a secondary analysis of the randomized protocol RTOG 86-10.

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

National practice patterns and time trends in androgen ablation for localized prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Prostate cancer DNA ploidy and response to salvage hormone therapy after radiotherapy with or without short-term total androgen blockade: an analysis of RTOG 8610.

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Radiation therapy after radical prostatectomy: A review of the issues and options

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Salvage radiotherapy for biochemical failure of radical prostatectomy: a single-institution experience

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Tolerance and early outcome results of postprostatectomy three-dimensional conformal radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

(IN)-efficacy of salvage radiotherapy for rising PSA or clinically isolated local recurrence after radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Radiotherapy for a rising prostate-specific antigen after radical prostatectomy: the first 10 years

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

The results of radiotherapy for isolated elevation of serum PSA levels following radical prostatectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Postoperative radiotherapy for stage pT3 carcinoma of the prostate: improved local control

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Postoperative radiotherapy in 423 patients with pT3N0 prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Comparison of the efficacy of local therapies for localized prostate cancer in the prostate-specific antigen era: a large single-institution experience with radical prostatectomy and external-beam radiotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Amifostine as radioprotective agent for the rectal mucosa during irradiation of pelvic tumors. A phase II randomized study using various toxicity scales and rectosigmoidoscopy

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

A randomized trial evaluating rigid immobilization for pelvic irradiation.

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Predictive factors of urinary retention following prostate brachytherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Bicalutamide as Immediate Therapy Either Alone or as Adjuvant to Standard Care of Patients with Localized or Locally Advanced Prostate Cancer: First Analysis of the Early Prostate Cancer Program

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

High-risk localized prostate cancer: primary surgery and adjuvant therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer: updated results of a multicentric trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

BICALUTAMIDE MONOTHERAPY COMPARED WITH CASTRATION IN PATIENTS WITH NONMETASTATIC LOCALLY ADVANCED PROSTATE CANCER: 6.3 YEARS OF FOLLOWUP

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Altered cognitive function in men treated for prostate cancer with luteinizing hormone-releasing hormone analogues and cyproterone acetate: a randomized controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Does prophylactic breast irradiation prevent antiandrogen-induced gynecomastia? Evaluation of 253 patients in the randomized Scandinavian trial SPCG-7/SFUO-3

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Variation in chromogranin A serum levels during intermittent versus continuous androgen deprivation therapy for prostate adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

A prospective and randomized study of primary hormonal therapy for patients with localized or locally advanced prostate cancer unsuitable for radical prostatectomy: results of the 5-year follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

The effect of micronized estradiol on bone turnover and calciotropic hormones in older men receiving hormonal suppression therapy for prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Transdermal estradiol therapy for advanced prostate cancer--forward to the past?

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Irinotecan plus cisplatin has substantial antitumor effect as salvage chemotherapy against germ cell tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Adjuvant chemohormonal therapy of high risk prostate carcinoma. Ten year results

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

The combination of estramustine and mitoxantrone in hormone-refractory prostate cancer: a phase II feasibility study conducted by the Hellenic Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Randomized, multicenter, phase II trial of two multicomponent regimens in androgen-independent prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Suppression of prostate cancer induced bone remodeling by the endothelin receptor A antagonist atrasentan

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Pregnancy and risk of renal cell cancer: a population-based study in Sweden

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Is there an association between hypertension and cancer mortality?

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Prevalence of renal cell carcinoma in patients with ESRD pre-transplantation: a pathologic analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Prognostic factors of renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Prognostic factors of renal cell carcinoma: a multivariate analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Prognostic value of ploidy and proliferation markers in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Prognostic significance of CA 125, CD44, and epithelial membrane antigen in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Analysis of Fas gene mutations on laser capture microdissected specimens from renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

PSF-TFE3 oncoprotein in papillary renal cell carcinoma inactivates TFE3 and p53 through cytoplasmic sequestration

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Conventional (clear cell) renal carcinoma metastases have greater bcl-2 expression than high-risk primary tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter is associated with conventional renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Telomerase activity in renal cell carcinoma by modified telomeric repeat amplification protocol assay

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Effect of intentional cryo-injury to the renal collecting system

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Percutaneous radio frequency ablation of small renal tumors: initial results

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Perfusion-modulated MR imaging-guided radiofrequency ablation of the kidney in a porcine model

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

High-intensity focused ultrasound ablation of rabbit kidney tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Focused Extracorporeal Pyrotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II study.

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

The new bisphosphonate, Zometa (zoledronic acid), decreases skeletal complications in both osteolytic and osteoblastic lesions: a comparison to pamidronate

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Cancer vaccine--Antigenics

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Interferon-gamma or granulocyte-macrophage colony-stimulating factor administered as adjuvants with a vaccine of irradiated autologous tumor cells from short-term cell line cultures: a randomized phase 2 trial of the cancer biotherapy research group

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

A phase II study of irinotecan in patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Thymidine phosphorylase and dihydropyrimidine dehydrogenase in renal cell carcinoma: relationship between histological parameters and chemosensitivity to 5-fluorouracil

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

1 reference

7 January 2021

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

AE-941, a multifunctional antiangiogenic compound: trials in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Expression of insulin-like growth factor I receptor and survival in patients with clear cell renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Does smoking status influence the prognosis of bladder cancer? A systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Oxidative DNA damage induced by a metabolite of 2-naphthylamine, a smoking-related bladder carcinogen

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Intakes of fruits and vegetables, carotenoids and vitamins A, E, C in relation to the risk of bladder cancer in the ATBC cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Time to abandon testing for microscopic haematuria in adults?

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Microscopic haematuria as a predictor of urological diseases among steel workers

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Isolated asymptomatic microhematuria: a cross-sectional analysis of test-positive and test-negative patients

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Hematuria home screening: repeat testing results

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Biomarker risk assessment and bladder cancer detection in a cohort exposed to benzidine

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Incidence of negative hematuria in patients with acute urinary lithiasis presenting to the emergency room with flank pain

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Reexamining the value of hematuria testing in patients with acute flank pain

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Endoscopic detection of transitional cell carcinoma with 5-aminolevulinic acid: results of 1012 fluorescence endoscopies

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

New diagnostic and prognostic tools in bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Screening and monitoring for bladder cancer: refining the use of NMP22

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Tumor markers in the diagnosis of primary bladder cancer. A systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Urine detection of survivin and diagnosis of bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Evaluation of fluorescence in situ hybridization as an ancillary tool to urine cytology in diagnosing urothelial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Noninvasive detection and prediction of bladder cancer by fluorescence in situ hybridization analysis of exfoliated urothelial cells in voided urine.

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Neural network using combined urine nuclear matrix protein-22, monocyte chemoattractant protein-1 and urinary intercellular adhesion molecule-1 to detect bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Molecular aspects of bladder cancer III. Prognostic markers of bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Can p53 staining be used to identify patients with aggressive superficial bladder cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Intravesical adjuvant chemotherapy for superficial transitional cell bladder carcinoma: results of a randomized trial with epirubicin comparing short-term versus long-term maintenance treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Factors explaining recurrence in patients undergoing chemoimmunotherapy regimens for frequently recurring superficial bladder carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Sufficient prophylactic efficacy with minor adverse effects by intravesical instillation of low-dose bacillus Calmette-Guérin for superficial bladder cancer recurrence

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Is repeated transurethral resection justified in patients with newly diagnosed superficial bladder cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

The value of a second transurethral resection in evaluating patients with bladder tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Impact of a second transurethral resection on the staging of T1 bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Natural history of surgically treated bladder carcinoma with extravesical tumor extension.

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Decreasing blood loss in patients treated with radical cystectomy: a prospective randomizes trial using a new stapling device

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

1 reference

7 January 2021

Improving and predicting radiosensitivity in muscle invasive bladder cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Disease specific survival as endpoint of outcome for bladder cancer patients following radical cystectomy

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

High-risk metastatic urothelial cancer: chances for cure?

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Gemcitabine plus epirubicin in patients with advanced urothelial carcinoma who are not eligible for platinum-based regimens

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Phase III trial of fluorouracil, interferon alpha-2b, and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic or unresectable urothelial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Weekly chemotherapy with docetaxel, gemcitabine and cisplatin in advanced transitional cell urothelial cancer: a phase II trial

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Phase II study of paclitaxel plus carboplatin in patients with advanced carcinoma of the urothelium and renal dysfunction (E2896): a trial of the Eastern Cooperative Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Phase I trial of intravesical gemcitabine in bacillus Calmette-Guérin-refractory transitional-cell carcinoma of the bladder.

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Antineoplastic activity of honey in an experimental bladder cancer implantation model: in vivo and in vitro studies

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Gene therapy: the challenges of translating laboratory research into clinical practice

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Increasing incidence of testicular cancer worldwide: a review

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Y chromosome haplogroups: a correlation with testicular dysgenesis syndrome?

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

New directions in testicular cancer; molecular determinants of oncogenesis and treatment success

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Absence of c-KIT and members of the epidermal growth factor receptor family in refractory germ cell cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Expression of peroxisome proliferator-activated receptors in human testicular cancer and growth inhibition by its agonists

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Routine chest X-rays have no additional value in the detection of relapse during routine follow-up of patients treated with chemotherapy for disseminated non-seminomatous testicular cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography with conventional assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcino

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Early prediction of treatment response to high-dose salvage chemotherapy in patients with relapsed germ cell cancer using [(18)F]FDG PET.

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Testicular microlithiasis: US follow-up

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Histology and clinical outcomes in patients with bilateral testicular germ cell tumors: the Memorial Sloan Kettering Cancer Center experience 1950 to 2001.

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Contralateral testicular biopsy procedure in patients with unilateral testis cancer: is it indicated?

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Endocrine function in patients treated for carcinoma in situ in the testis with irradiation

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Cardiovascular morbidity in long-term survivors of metastatic testicular cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

The lack of long-term effect of Cisplatin based combination chemotherapy on serum cholesterol for treatment of testicular cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Cardiovascular Disease as a Long-Term Complication of Treatment for Testicular Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Etoposide VP 16--213)--a podophyllotoxinderivative with high antitumor activity (author's transl)

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Stage I seminoma of the testis: a bi-institutional retrospective analysis of patients treated with radiation therapy only

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Prognostic Factors for Relapse in Stage I Seminoma Managed by Surveillance: A Pooled Analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Comparison of surveillance and retroperitoneal lymph node dissection in Stage I nonseminomatous germ cell tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Complications of primary nerve sparing retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell tumors of the testis: experience of the German Testicular Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Risk Factors for Relapse in Clinical Stage I Nonseminomatous Testicular Germ Cell Tumors: Results of the German Testicular Cancer Study Group Trial

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Is post-chemotherapy resection of seminomatous elements associated with higher acute morbidity?

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Metastatic nonseminomatous germ cell tumors of the testis

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Prognostic variables for response and outcome in patients with extragonadal germ-cell tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Intensive induction chemotherapy with CBOP/BEP in patients with poor prognosis germ cell tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0921-4410%2804%2922022-1

7 January 2021

10.1016/S0921-4410(04)22022-1

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16110626%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16110626%20AND%20SRC:MED&resulttype=core&format=json